Important News for Geron Corporation Investors: Class Action Lawsuit Announcement
SAN DIEGO, CA – March 14, 2025
In a recent press release, the law firm of Robbins Geller Rudman & Dowd LLP announced that investors or acquirers of Geron Corporation (NASDAQ: GERN) securities between June 7, 2024, and February 25, 2025, inclusive (the “Class Period”), have until May 12, 2025, to seek appointment as lead plaintiff in a class action lawsuit against Geron Corporation. The lawsuit, captioned Dabestani v. Geron Corporation, alleges that the company and certain of its top executives violated the Securities Exchange Act of 1934.
What Does This Mean for Individual Investors?
If you are an individual investor who purchased or acquired Geron Corporation securities during the Class Period, you may be eligible to participate in the class action lawsuit. The lead plaintiff is the investor who proposes to take initial steps in the litigation on behalf of all class members. The lead plaintiff will be a court-appointed representative for all class members. If you wish to serve as lead plaintiff, you must meet certain requirements and must file a motion with the court before the deadline.
How Will This Affect the World?
The impact of this class action lawsuit on the wider world depends on the outcome of the litigation. If the allegations of securities fraud are proven, it could potentially lead to significant financial consequences for Geron Corporation and its executives. This could include fines, damages, and other penalties. Moreover, the lawsuit could also result in increased scrutiny of the biotech industry’s regulatory compliance and corporate governance practices.
What’s Next for Geron Corporation?
- The class action lawsuit is in its early stages, and it’s important to note that the allegations have not been proven in court.
- Geron Corporation has not yet responded to the allegations publicly.
- Investors who are considering buying or selling Geron Corporation securities should closely monitor the situation and consult with their financial advisors.
As this is a developing story, we will continue to provide updates as more information becomes available.
Conclusion
The announcement of a class action lawsuit against Geron Corporation by Robbins Geller Rudman & Dowd LLP is an important development for investors who purchased or acquired the company’s securities between June 7, 2024, and February 25, 2025. If you are an eligible investor, you have until May 12, 2025, to seek appointment as lead plaintiff. The outcome of the litigation could have significant financial consequences for Geron Corporation and its executives, as well as broader implications for the biotech industry. Stay tuned for updates.
